Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
DUPRO steering committee and PROTECT Investigators
- The Ohio State University Wexner Medical Center
- College of Life Sciences
- University of Groningen
- Macquarie University, Australian School of Advanced Medicine
- University of Washington, Seattle
- Travere Therapeutics
- Seoul Red Cross Hospital
- RWTH Aachen University
- Aldo Moro University of Bari
- University of Utah
- Colorado Kidney Care
- Stanford University
- AZ Delta
- Międzyleski Specialist Hospital
- JAMCO Pharma Consulting
- University of Sao Paulo
- Korea University Anam Hospital
- Royal Adelaide Hospital
- Research Institute Hospital 12 de Octubre (i+12)
- Universidad Complutense de Madrid
- Columbia University Medical Center
- University of Minnesota Medical School
- The University of Hong Kong
- Charles University
- University of Michigan
- Buenos Aires British Hospital
- Emory University
- NephroNet Clinical Trials Consortium
- Concord Repatriation General Hospital
- Westmead Hospital & Sydney Medical School
273
Link opens in a new tab
Citations
(Scopus)